CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Geovax Labs Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Geovax Labs Inc
1955 Lake Park Drive, Suite 300
Phone: (302) 658-7581p:302 658-7581 SMYRNA, GA  30080  United States Fax: (302) 655-5049f:302 655-5049
Business Summary
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. Its lead clinical program is GEO-CM04S1, a COVID-19 vaccine, which is in three phase II clinical trials, being evaluated as a primary vaccine for immunocompromised patients, such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient; a booster vaccine in patients with chronic lymphocytic leukemia (CLL); and a COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, having completed a multicenter Phase I/II clinical trial for advanced head and neck cancers. It is developing GEO-MVA, a vaccine targeting Mpox and smallpox. Its other product candidates include GEO-EM01-Z, GEO-EM01-S, GEO-MM01, GEO-ZM02 and others.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
3571 Electronic computers
3699 Electrical machinery, equipment, and supplies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer David A.Dodd 75 9/5/2018 3/17/2010
CFO MARK .REYNOLDS
CFO MARK .REYNOLDS
9 additional Officers and Directors records available in full report.

Business Names
Business Name
DNTK
GeoVax Labs, Inc.
GeoVax, Inc.
GOVX
GOVXD
Immutak Oncology, Inc.

General Information
Number of Employees: 19 (As of 12/31/2025)
Outstanding Shares: 2,892,570 (As of 4/15/2026)
Shareholders: 25
Stock Exchange: NASD
Federal Tax Id: 870455038
Fax Number: (302) 655-5049


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, May 12, 2026